Novocure Stock

Novocure Gross Margin

The Gross Margin of Novocure (NVCR) as of Aug 21, 2026 is 74.54 %. In the previous year, Gross Margin was 77.33 % — a change of -3.62% (lower).

Gross Margin

74.54 %

YoY

-3.62%

Last updated:

Gross Margin of Novocure is 2026 74.54 % . Gross Margin of Novocure was 2025 77.33 % . It decreases by -3.62% lower compared to the previous year.

Novocure's gross margin stands at 74.5%, down from 78.5% several years earlier.

Access this data via the Eulerpool API

Novocure Stock analysis

What does Novocure do? Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novocure stock

Gross Margin of Novocure is 74.54 % in 2026.

Gross Margin of Novocure changed from 77.33 % to 74.54 %, representing a -3.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Novocure since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Novocure with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Novocure

All Key Metrics — Novocure